The breast cancer therapy market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio / Verzenios) are creating new dynamics in the metastatic HR-positive / HER2-negative treatment practice. In HER2-positive breast cancer, HER2-targeting drugs are in development and will enter the market, and sales of current HER2-targeting agents will be impacted as a result of the competition, label expansions, biosimilar entries, and new trials leading to changes in treatment guidelines. Furthermore, the approval of PARP inhibitors (AstraZeneca / Merck & Co.’s Lynparza and Pfizer’s Talzenna), PD-1-targeting agents (Roche / Genentech / Chugai’s Tecentriq), PI3K inhibitors (Novartis’s Piqray), HER2-targeting agents (Daiichi Sankyo / AstraZeneca’s Enhertu, Seagen’s Tukysa, and MacroGenics’ Margenza), TROP2-targeting antibody-drug conjugates (Immunomedics’ Trodelvy), and the anticipated entry of other agents from these drug classes will diversify treatment options, especially for triple-negative breast cancer.

Questions answered

  • What is the size of the drug-treatable breast cancer population, and how will drug-treatment rates change over time?
  • What is the expected market impact of recent drug approvals, such as Tecentriq, Piqray, Enhertu, Tukysa, and Trodelvy on the various subpopulations of breast cancer?
  • What are the most promising agents in the pipeline, and how will they shape the future of the breast cancer therapy market?
  • What are the drivers and constraints in the breast cancer market, and how will the market evolve over the forecast period?

Content Highlights

  • Geographies: United States, EU5, Japan
  • Primary research: 19 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research
  • Epidemiology: Incidence of breast cancer by country, segmented by HR and HER2 status, staging, and line of therapy
  • Forecast: 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2029, segmented by brands / biosimilars / generics and market-relevant drug-treatable populations
  • Emerging therapies: Phase III/PR: 15 drugs; coverage of select Phase I and II products

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Breast Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q3 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
      • Q3 2020
        • August 2020
    • Key Findings
      • Breast Cancer – Key Findings – July 2021
        • August 2020
    • Market Outlook
      • Key Findings
        • Market Share of Breast Cancer Drug Classes: 2019
        • Market Share of Breast Cancer Drug Classes: 2029
        • Drug-Treatable Population Share and Major-Market Sales Share in Breast Cancer: 2019
        • Drug-Treatable Population Share and Major-Market Sales Share in Breast Cancer: 2029
        • Population Positioning of Therapies in Breast Cancer
        • SWOT Analysis
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Breast Cancer?
        • What Factors Are Constraining the Market for Breast Cancer?
      • Segment-Specific Trends
        • Patient-Share Dynamics of Key Branded Agents in (Neo)Adjuvant HR-Positive / HER2-Negative Breast Cancer in the United States: 2019-2029
        • Patient-Share Dynamics of Key Agents in (Neo)Adjuvant HR-Positive / HER2-Positive Breast Cancer in the United States: 2019-2029
        • Patient-Share Dynamics of Key Agents in (Neo)Adjuvant Triple-Negative Breast Cancer in the United States: 2019-2029
        • Patient-Share Dynamics of Key Agents for First-Line HR-Positive / HER2-Negative Breast Cancer in the United States: 2019-2029
        • Patient-Share Dynamics of Key Agents in First-Line HER2-Positive Breast Cancer in the United States: 2019-2029
        • Patient-Share Dynamics of Key Agents for First-Line Triple-Negative Breast Cancer in the United States: 2019-2029
        • Patient-Share Dynamics of Key Agents for First-Line Triple-Negative Breast Cancer in Germany: 2019-2029
        • Patient-Share Dynamics of Key Agents in Second-Line HR-Positive / HER2-Negative Breast Cancer in the United States: 2019-2029
        • Patient-Share Dynamics of Key Agents in Third-Line HR-Positive / HER2-Negative Breast Cancer in the United States: 2019-2029
        • Patient-Share Dynamics of Key Agents in Second-Line HER2-Positive Breast Cancer in the United States: 2019-2029
        • Patient-Share Dynamics of Key Agents in Third-Line HER2-Positive Breast Cancer in the United States: 2019-2029
        • Patient-Share Dynamics of Key Agents in Second-Line Triple-Negative Breast Cancer in the United States: 2019-2029
        • Patient-Share Dynamics of Key Agents in Third-Line Triple-Negative Breast Cancer in the United States: 2019-2029
    • Forecast
      • Market Forecast Downloads
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Pathophysiology
          • Prognostic Biomarkers
          • Patterns of Metastasis
          • Patterns of Metastatic Spread in Breast Cancer
        • Staging and Classification
          • Staging of Breast Cancer
          • Definitions of TNM Staging Classifications of Breast Cancer
          • TNM Staging System for Classification of Breast Cancer
        • Prognostic Gene Expression Signatures
          • Oncotype DX
          • MammaPrint
          • Breast Cancer Index
        • Key Pathways and Drug Targets
          • Key Pathways and Drug Targets for Breast Cancer
          • Schematic Diagram of the PI3K/AKT/mTOR Pathway
          • PARP Inhibition: Mechanism of Action
          • Mechanism by Which Bone Metastasis Occurs in Breast Cancer
          • Immune Checkpoint Activation and Pathways
      • Epidemiology
        • Key Findings
          • Epidemiology Populations
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Incidence of Breast Cancer
            • Diagnosed Incident Cases of Breast Cancer in the Major Pharmaceutical Markets: 2019-2029
            • Disease Definition
            • Methods
            • Sources Used for Molecular Subtype of Breast Cancer
            • Diagnosed Incident Cases of Breast Cancer by Molecular Subtype: 2019-2029
            • Disease Definition
            • Methods
            • Sources Used for Stage Distribution of Breast Cancer
            • Diagnosed Incident Cases of Breast Cancer (All Subtypes) by Stage at Diagnosis: 2019-2029
            • Diagnosed Incident Cases of HR-Positive / HER2-Negative Breast Cancer by Stage at Diagnosis: 2019-2029
            • Diagnosed Incident Cases of HR-Positive / HER2-Positive Breast Cancer by Stage at Diagnosis: 2019-2029
            • Diagnosed Incident Cases of HR-Negative / HER2-Positive Breast Cancer by Stage at Diagnosis: 2019-2029
            • Diagnosed Incident Cases of HR-Negative / HER2-Negative Breast Cancer by Stage at Diagnosis: 2019-2029
            • Disease Definition
            • Methods
            • Sources Used for Menopausal Status of Breast Cancer
            • Diagnosed Incident Cases of Hormonal (HR-Positive) Breast Cancer by Menopausal Status: 2019-2029
            • Breast Cancer Patient Flow
            • Drug-Treatable Cases of HER2-Positive (HR-Positive and -Negative) Breast Cancer in the Major Pharmaceutical Markets: 2019-2029
            • Drug-Treatable Cases of HR-Positive / HER2-Negative Breast Cancer in the Major Pharmaceutical Markets: 2019-2029
            • Drug-Treatable Cases of HR-Negative / HER2-Negative (Triple-Negative) Breast Cancer in the Major Pharmaceutical Markets: 2019-2029
            • Sources Used for Drug-Treated Breast Cancer Populations
            • Drug-Treated Cases of Breast Cancer in the Major Pharmaceutical Markets: 2019-2029
            • Drug-Treated Cases of HER2-Positive (HR-Positive and -Negative) Breast Cancer in the Major Pharmaceutical Markets: 2019-2029
            • Drug-Treated Cases of HR-Positive / HER2-Negative Breast Cancer in the Major Pharmaceutical Markets: 2019-2029
            • Drug-Treated Cases of HR-Negative / HER2-Negative (Triple-Negative) Breast Cancer in the Major Pharmaceutical Markets: 2019-2029
        • Current Treatment
          • Key Findings
            • Treatment Goals
              • Key Endpoints Used in Clinical Trials for Breast Cancer
            • Key Current Therapies
              • Overview
              • Mechanism of Action of Key Current Drug Classes Used for Breast Cancer
              • Current Treatments Used for Breast Cancer
              • Market Events Impacting the Use of Key Current Therapies for Breast Cancer
              • Key Results from Select Clinical Trials Investigating Trastuzumab for the Treatment of Breast Cancer
              • Ongoing Clinical Development of Trastuzumab
              • Expert Insight: Trastuzumab
              • Key Results from Select Clinical Trials Investigating Perjeta for the Treatment of Breast Cancer
              • Ongoing Clinical Development of Perjeta
              • Key Ongoing Clinical Trials of Perjeta in the Treatment of Breast Cancer
              • Expert Insight: Perjeta
              • Key Results from Select Clinical Trials Investigating Kadcyla for the Treatment of Breast Cancer
              • Ongoing Clinical Development of Kadcyla
              • Key Ongoing Clinical Trials of Kadcyla in the Treatment of Breast Cancer
              • Expert Insight: Kadcyla
              • Key Results from Select Clinical Trials Investigating Tykerb / Tyverb for the Treatment of Breast Cancer
              • Expert Insight: Tykerb / Tyverb
              • Key Results from Select Clinical Trials Investigating Nerlynx for the Treatment of Breast Cancer
              • Ongoing Clinical Development of Nerlynx
              • Key Ongoing Clinical Trials of Nerlynx in the Treatment of Breast Cancer
              • Expert Insight: Nerlynx
              • Key Results from Select Clinical Trials Investigating Enhertu for the Treatment of Breast Cancer
              • Ongoing Clinical Development of Enhertu
              • Key Ongoing Clinical Trials of Enhertu in the Treatment of Breast Cancer
              • Expert Insight: Enhertu
              • Tukysa
              • Key Results from Select Clinical Trials Investigating Tukysa for the Treatment of Breast Cancer
              • Ongoing Clinical Development of Tukysa
              • Key Ongoing Clinical Trials of Tukysa in the Treatment of Breast Cancer
              • Expert Insight: Tukysa
              • Key Results from Select Clinical Trials Investigating Margenza for the Treatment of Breast Cancer
              • Ongoing Clinical Development of Margenza
              • Key Ongoing Clinical Trials of Margenza in the Treatment of Breast Cancer
              • Expert Insight: Margenza
              • Key Results from Select Clinical Trials Investigating Ibrance for the Treatment of Breast Cancer
              • Ongoing Clinical Development of Ibrance
              • Key Ongoing Clinical Trials of Ibrance in the Treatment of Breast Cancer
              • Expert Insight: Ibrance
              • Key Results from Select Clinical Trials Investigating Kisqali for the Treatment of Breast Cancer
              • Ongoing Clinical Development of Kisqali
              • Key Ongoing Clinical Trials of Kisqali in the Treatment of Breast Cancer
              • Expert Insight: Kisqali
              • Key Results from Select Clinical Trials Investigating Verzenio / Verzenios for the Treatment of Breast Cancer
              • Ongoing Clinical Development of Verzenio / Verzenios
              • Key Ongoing Clinical Trials of Verzenio / Verzenios in the Treatment of Breast Cancer
              • Expert Insight: Verzenio / Verzenios
              • Key Results from Select Clinical Trials Investigating Everolimus for the Treatment of Breast Cancer
              • Ongoing Clinical Development of Everolimus
              • Key Ongoing Clinical Trials of Everolimus in the Treatment of Breast Cancer
              • Expert Insight: Everolimus
              • Key Results from Select Clinical Trials Investigating Bevacizumab for the Treatment of Breast Cancer
              • Expert Insight: Bevacizumab
              • Key Results from Select Clinical Trials Investigating Abraxane for the Treatment of Breast Cancer
              • Expert Insight: Abraxane
              • Key Results from Select Clinical Trials Investigating Halaven for the Treatment of Breast Cancer
              • Expert Insight: Halaven
              • Key Results from Select Clinical Trials Investigating Fulvestrant for the Treatment of Breast Cancer
              • Expert Insight: Fulvestrant
              • Key Results from Select Clinical Trials Investigating Lynparza for the Treatment of Breast Cancer
              • Ongoing Clinical Development of Lynparza
              • Key Ongoing Clinical Trials of Lynparza in the Treatment of Breast Cancer
              • Expert Insight: Lynparza
              • Key Results from Select Clinical Trials Investigating Talzenna for the Treatment of Breast Cancer
              • Ongoing Clinical Development for Talzenna
              • Key Ongoing Clinical Trials of Talzenna in Breast Cancer
              • Expert Insight: Talzenna
              • Key Results from Select Clinical Trials Investigating Tecentriq for the Treatment of Breast Cancer
              • Ongoing Clinical Development for Tecentriq
              • Key Ongoing Clinical Trials of Tecentriq in the Treatment of Breast Cancer
              • Expert Insight: Tecentriq
              • Key Results from Select Clinical Trials Investigating Keytruda for the Treatment of Breast Cancer
              • Ongoing Clinical Development for Keytruda
              • Key Ongoing Clinical Trials of Keytruda in the Treatment of Breast Cancer
              • Expert Insight: Keytruda
              • Key Results from Select Clinical Trials Investigating Piqray for the Treatment of Breast Cancer
              • Ongoing Clinical Development for Piqray
              • Key Ongoing Clinical Trials of Piqray in the Treatment of Breast Cancer
              • Expert Insight: Piqray
              • Trodelvy
              • Key Results from Select Clinical Trials Investigating Trodelvy for the Treatment of Breast Cancer
              • Ongoing Clinical Development of Trodelvy
              • Key Ongoing Clinical Trials of Trodelvy in the Treatment of Breast Cancer
              • Expert Insight: Trodelvy
            • Medical Practice
              • Neoadjuvant Treatment of Stage II/III Breast Cancer
              • Adjuvant Treatment of Stage I-III Breast Cancer
              • First-Line Treatment of Advanced / Metastatic Breast Cancer
              • Second- and Subsequent-Line Treatment of Advanced / Metastatic Breast Cancer
              • Country-Specific Breast Cancer Treatment Guidelines
              • Patient Characteristics Influencing Drug Selection in Breast Cancer
              • Treatment Decision Tree for Early-Stage Breast Cancer: United States
              • Treatment Decision Tree for Metastatic Breast Cancer: United States
              • Treatment Decision Tree for Early-Stage Breast Cancer: Europe
              • Treatment Decision Tree for Metastatic Breast Cancer: Europe
              • Treatment Decision Tree for Early-Stage Breast Cancer: Japan
              • Treatment Decision Tree for Metastatic Breast Cancer: Japan
          • Unmet Need Overview
            • Current and Future Attainment of Unmet Needs in Breast Cancer
            • Top Unmet Needs in Breast Cancer: Current and Future Attainment
          • Emerging Therapies
            • Key Findings
              • Pipeline Trends in Breast Cancer
            • Key Emerging Therapies
              • Key Therapies in Development for Breast Cancer
              • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Breast Cancer
              • Key Results from Select Clinical Trials Investigating Veliparib for the Treatment of Breast Cancer
              • Key Ongoing Trials of Veliparib in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Veliparib
              • Expert Insight: Veliparib
              • Expectations for Market Authorization and Sales Opportunity of Veliparib in Breast Cancer
              • Key Results from Select Clinical Trials Investigating Ipatasertib for the Treatment of Breast Cancer
              • Key Ongoing Trials of Ipatasertib in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Ipatasertib
              • Expert Insight: Ipatasertib
              • Expectations for Market Authorization and Sales Opportunity of Ipatasertib in Breast Cancer
              • Key Results from Select Clinical Trials Investigating Capivasertib for the Treatment of Breast Cancer
              • Key Ongoing Trials of Capivasertib in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Capivasertib
              • Expert Insight: Capivasertib
              • Expectations for Market Authorization and Sales Opportunity of Capivasertib in Breast Cancer
              • GDC-0077
              • Key Results from Select Clinical Trials Investigating GDC-0077 for the Treatment of Breast Cancer
              • Key Ongoing Clinical Trials of GDC-0077 in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for GDC-0077
              • Expert Insight: GDC-0077
              • Expectations for Market Authorization and Sales Opportunity of GDC-0077 in Breast Cancer
              • Key Results from Select Clinical Trials Investigating Bavencio for the Treatment of Breast Cancer
              • Key Ongoing Clinical Trials of Bavencio in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Bavencio
              • Expert Insight: Bavencio
              • Expectations for Market Authorization and Sales Opportunity of Bavencio in Breast Cancer
              • Key Results from Select Clinical Trials Investigating Opdivo for the Treatment of Breast Cancer
              • Key Ongoing Trials of Opdivo in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Opdivo
              • Expert Insight: Opdivo
              • Expectations for Market Authorization and Sales Opportunity of Opdivo in Breast Cancer
              • Key Results from Select Clinical Trials Investigating Trastuzumab Duocarmazine for the Treatment of Breast Cancer
              • Key Ongoing Trials of Trastuzumab Duocarmazine in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Trastuzumab Duocarmazine
              • Expert Insight: Trastuzumab Duocarmazine
              • Expectations for Market Authorization and Sales Opportunity of Trastuzumab Duocarmazine in Breast Cancer
              • Key Results from Select Clinical Trials Investigating Trilaciclib for the Treatment of Breast Cancer
              • Key Ongoing Clinical Trials of Trilaciclib in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Trilaciclib
              • Expectations for Market Authorization and Sales Opportunity of Trilaciclib in Breast Cancer
              • Key Results from Select Clinical Trials Investigating Tesetaxel for the Treatment of Breast Cancer
              • Key Ongoing Clinical Trials of Tesetaxel in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Tesetaxel
              • Expert Insight: Tesetaxel
              • Expectations for Market Authorization and Sales Opportunity of Tesetaxel in Breast Cancer
              • Key Results from Select Clinical Trials Investigating Oraxol for the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Oraxol
              • Expert Insight: Oraxol
              • Expectations for Market Authorization and Sales Opportunity of Oraxol in Breast Cancer
              • Key Results from Select Clinical Trials Investigating Adagloxad Simolenin / OBI-821 for the Treatment of Breast Cancer
              • Key Ongoing Trials of Adagloxad Simolenin / OBI-821 in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Adagloxad Simolenin / OBI-821
              • Expert Insight: Adagloxad Simolenin / OBI-821
              • Expectations for Market Authorization and Sales Opportunity of Adagloxad Simolenin / OBI-821 in Breast Cancer
              • Key Results from Select Clinical Trials Investigating Balixafortide for the Treatment of Breast Cancer
              • Key Ongoing Trials of Balixafortide in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Balixafortide
              • Expert Insight: Balixafortide
              • Expectations for Market Authorization and Sales Opportunity of Balixafortide in Breast Cancer
              • Key Results from Select Clinical Trials Investigating Elacestrant for the Treatment of Breast Cancer
              • Key Ongoing Trials of Elacestrant in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Elacestrant
              • Expert Insight: Elacestrant
              • Expectations for Market Authorization and Sales Opportunity of Elacestrant in Breast Cancer
              • Key Results from Select Clinical Trials Investigating Giredestrant for the Treatment of Breast Cancer
              • Key Ongoing Clinical Trials of Giredestrant in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Giredestrant
              • Expectations for Market Authorization and Sales Opportunity of Giredestrant in Breast Cancer
              • Key Results from Select Clinical Trials Investigating Amcenestrant for the Treatment of Breast Cancer
              • Key Ongoing Clinical Trials of Amcenestrant in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Amcenestrant
              • Expectations for Market Authorization and Sales Opportunity of Amcenestrant in Breast Cancer
              • Key Results from Select Clinical Trials Investigating Camizestrant for the Treatment of Breast Cancer
              • Key Ongoing Clinical Trials of Camizestrant in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Camizestrant
              • Expectations for Market Authorization and Sales Opportunity of Camizestrant in Breast Cancer
              • Key Ongoing Trials of Lasofoxifene in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Lasofoxifene
              • Expert Insight: Lasofoxifene
              • Expectations for Market Authorization and Sales Opportunity of Lasofoxifene in Breast Cancer
              • Key Results from Select Clinical Trials Investigating Enobosarm for the Treatment of Breast Cancer
              • Key Ongoing Clinical Trials of Enobosarm in the Treatment of Breast Cancer
              • Analysis of the Clinical Development Program for Enobosarm
              • Expectations for Market Authorization and Sales Opportunity of Enobosarm in Breast Cancer
            • Early-Phase Pipeline Analysis
              • Select Compounds in Early-Phase Development for Breast Cancer
          • Access and Reimbursement Overview
            • Region-Specific Reimbursement Practices
              • General Reimbursement Environment: United States
              • General Reimbursement Environment: EU5
              • General Reimbursement Environment: Japan
          • Appendix
            • Key Abbreviations Related to Breast Cancer
            • Brands, Marketers, and Generic Availability of Key Therapies for Breast Cancer by Market
            • Breast Cancer Bibliography

        Author(s): Carolina do Pazo, M.Sc.; Alexandre Vo Dupuy, Pharm.D., M.Sc.

        Carolina do Pazo, M.Sc., is a senior analyst on the Oncology team at Clarivate. She has authored content on breast cancer, SCCHN, ovarian cancer, and prostate cancer. Previously, she was a research scientist at the Institut Pasteur de Montevideo, where she analyzed the aging process of yeast cells, and she was part of a project between Indiana University and the Universidad ORT that analyzed the production of nanohybrids for drug delivery system applications. As a Chevening Scholar, Ms. Do Pazo completed an M.Sc. in biotechnology, bioprocessing, and business management with distinction at the University of Warwick. She also earned her first-class M.Eng. in biotechnology from the Universidad ORT.

        Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux.


        Related Reports

        Breast Cancer - Current Treatment - Detailed, Expanded Analysis (EU5)

        KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into...

        View Details

        Breast Cancer - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (EU5)

        KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

        View Details

        Breast Cancer | Disease Landscape and Forecast | G7 | 2020

        The breast cancer market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio / Verze...

        View Details

        Breast Cancer | China In-Depth | China | 2020

        Breast cancer is the most commonly diagnosed cancer among Chinese women. A high incidence and a prolonged treatment duration make the treatment of breast cancer a lucrative commercial opportunity f...

        View Details